Upon review of the proposed supplemental New Drug Application (sNDA), the FDA has determined that the communication plan is no longer needed as an element of the REMS to ensure the benefits of Afrezza outweigh its risks.
FDA: REMS No Longer Needed for Inhaled Insulin Afrezza posted first on https://www.youtube.com/dailyhealthpost/
No comments:
Post a Comment